Hope for ALS patients denied entry to clinical trials
Disease control
NO_LONGER_AVAILABLE
This program provided access to an experimental ALS treatment called SLS-005 for patients who couldn't join regular clinical trials. Approximately 70 participants received weekly intravenous infusions of trehalose for up to 24 weeks. The goal was to offer this investigational tre…
Sponsor: Seelos Therapeutics, Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC